Analyst Research

Report Title Price
Provider: ValuEngine, Inc.
Provider: ValuEngine, Inc.
Provider: S&P Capital IQ – STARS Reports
Provider: Reuters Investment Profile

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Medy Tox Inc Signs Technology Licensing Contract with Allergan, Inc.

Wednesday, 25 Sep 2013 06:05pm EDT 

Medy Tox Inc announced that it has signed a contract with Allergan, Inc., a Delaware-based corporation, and its subsidiaries, Allergan Pharmaceuticals Ireland, a company incorporated in Ireland, and Allergan Pharmaceuticals Holdings (Ireland), an unlimited company incorporated in Ireland (collectively referred to as “Allergan”), for the development and sale of neurotoxin candidate products. Allergan, Inc. was licensed with the exclusive development and distribution right in the United States, and other entities of Allergan will be the exclusive distributor of the Company's products in markets expect Korea. The contract amount is KRW 389,801,600,000 (USD 362,000,000). 

Company Quote

0.027 +0.37%
11:22am EDT